Onduarp

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Prospect Prospect (PIL)
02-04-2014

Ingredient activ:

Telmisartan

Disponibil de la:

Boehringer Ingelheim International GmbH

Codul ATC:

C09DB04

INN (nume internaţional):

telmisartan, amlodipine

Grupul Terapeutică:

Cardiovascular system

Zonă Terapeutică:

Hypertension

Indicații terapeutice:

Treatment of essential hypertension in adults:Add on therapyOnduarp is indicated in adults whose blood pressure is not adequately controlled on amlodipine.Replacement therapyAdult patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of Onduarp containing the same component doses.

Rezumat produs:

Revision: 2

Statutul autorizaţiei:

Withdrawn

Data de autorizare:

2011-11-24

Prospect

                                96
B. PACKAGE LEAFLET
Medicinal product no longer authorised
97
PACKAGE LEAFLET: INFORMATION FOR THE USER
ONDUARP 40 MG/5 MG TABLETS
Telmisartan/Amlodipine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any of the side effects, talk to your doctor or pharmacist.
This includes any possible
side effects not listed in this leaflet.
WHAT IS IN THIS LEAFLET:
1.
What Onduarp is and what it is used for
2.
What you need to know before you take Onduarp
3.
How to take Onduarp
4.
Possible side effects
5.
How to store Onduarp
6.
Contents of the pack and other information
1.
WHAT ONDUARP IS AND WHAT IT IS USED FOR
_ _
Onduarp tablets contain two active substances called telmisartan and
amlodipine. Both of these
substances help to control your high blood pressure:
- Telmisartan belongs to a group of substances called
“angiotensin-II receptor antagonists”.
Angiotensin II is a substance produced in the body which causes blood
vessels to narrow, thus
increasing blood pressure. Telmisartan works by blocking the effect of
angiotensin II.
- Amlodipine belongs to a group of substances called “calcium
channel blockers”. Amlodipine stops
calcium from moving into the blood vessel wall which stops the blood
vessels from tightening.
This means that both of these active substances work together to help
stop your blood vessels
tightening. As a result, the blood vessels relax and blood pressure is
lowered.
ONDUARP IS USED TO treat high blood pressure
- in adult patients whose blood pressure is not controlled enough with
amlodipine.
- in adult patients who already receive telmisartan and amlodipine
from separate tablets and who wish
to take instead the same doses in one tablet for
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
Onduarp 40 mg/5 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_ _
Each tablet contains 40 mg telmisartan and 5 mg amlodipine (as
amlodipine besilate).
Excipient(s) with known effect
:
Each tablet contains 168.64 mg sorbitol (E420).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Blue and white oval shaped two layer tablets engraved with the product
code A1 and the company
logo on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of essential hypertension in adults:
Add on therapy
Onduarp is indicated in adults whose blood pressure is not adequately
controlled on amlodipine.
Replacement therapy
Adult patients receiving telmisartan and amlodipine from separate
tablets can instead receive tablets of
Onduarp containing the same component doses.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose of Onduarp is one tablet per day.
The maximum recommended dose is Onduarp 80 mg/10 mg, one tablet per
day. Onduarp is indicated
for long term treatment.
Administration of amlodipine with grapefruit or grapefruit juice is
not recommended as bioavailability
may be increased in some patients resulting in increased blood
pressure lowering effects (see section
4.5).
_Add on therapy_
_ _
Onduarp 40 mg/5 mg tablets may be administered in patients whose blood
pressure is not adequately
controlled with amlodipine 5 mg alone.
Individual dose titration with the components (i.e. amlodipine and
telmisartan) is recommended before
changing to the fixed dose combination. When clinically appropriate,
direct change from monotherapy
to the fixed combination may be considered.
Medicinal product no longer authorised
3
Patients treated with 10 mg amlodipine who experience any dose
limiting adverse reactions such as
oedema, may be switched to Onduarp 40 mg/5 mg once daily, reducing the
dose of amlodipine
without reducing the overall expected an
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului bulgară 02-04-2014
Raport public de evaluare Raport public de evaluare bulgară 02-04-2014
Prospect Prospect spaniolă 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului spaniolă 02-04-2014
Raport public de evaluare Raport public de evaluare spaniolă 02-04-2014
Prospect Prospect cehă 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului cehă 02-04-2014
Raport public de evaluare Raport public de evaluare cehă 02-04-2014
Prospect Prospect daneză 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului daneză 02-04-2014
Raport public de evaluare Raport public de evaluare daneză 02-04-2014
Prospect Prospect germană 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului germană 02-04-2014
Raport public de evaluare Raport public de evaluare germană 02-04-2014
Prospect Prospect estoniană 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului estoniană 02-04-2014
Raport public de evaluare Raport public de evaluare estoniană 02-04-2014
Prospect Prospect greacă 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului greacă 02-04-2014
Raport public de evaluare Raport public de evaluare greacă 02-04-2014
Prospect Prospect franceză 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului franceză 02-04-2014
Raport public de evaluare Raport public de evaluare franceză 02-04-2014
Prospect Prospect italiană 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului italiană 02-04-2014
Raport public de evaluare Raport public de evaluare italiană 02-04-2014
Prospect Prospect letonă 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului letonă 02-04-2014
Raport public de evaluare Raport public de evaluare letonă 02-04-2014
Prospect Prospect lituaniană 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului lituaniană 02-04-2014
Raport public de evaluare Raport public de evaluare lituaniană 02-04-2014
Prospect Prospect maghiară 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului maghiară 02-04-2014
Raport public de evaluare Raport public de evaluare maghiară 02-04-2014
Prospect Prospect malteză 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului malteză 02-04-2014
Raport public de evaluare Raport public de evaluare malteză 02-04-2014
Prospect Prospect olandeză 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului olandeză 02-04-2014
Raport public de evaluare Raport public de evaluare olandeză 02-04-2014
Prospect Prospect poloneză 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului poloneză 02-04-2014
Raport public de evaluare Raport public de evaluare poloneză 02-04-2014
Prospect Prospect portugheză 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului portugheză 02-04-2014
Raport public de evaluare Raport public de evaluare portugheză 02-04-2014
Prospect Prospect română 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului română 02-04-2014
Raport public de evaluare Raport public de evaluare română 02-04-2014
Prospect Prospect slovacă 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului slovacă 02-04-2014
Raport public de evaluare Raport public de evaluare slovacă 02-04-2014
Prospect Prospect slovenă 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului slovenă 02-04-2014
Raport public de evaluare Raport public de evaluare slovenă 02-04-2014
Prospect Prospect finlandeză 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului finlandeză 02-04-2014
Raport public de evaluare Raport public de evaluare finlandeză 02-04-2014
Prospect Prospect suedeză 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului suedeză 02-04-2014
Raport public de evaluare Raport public de evaluare suedeză 02-04-2014
Prospect Prospect norvegiană 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului norvegiană 02-04-2014
Prospect Prospect islandeză 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului islandeză 02-04-2014
Prospect Prospect croată 02-04-2014
Caracteristicilor produsului Caracteristicilor produsului croată 02-04-2014

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor